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IntroductIon
Obesity is a major public health problem, particularly among 
African Americans (AAs). In 2008, the prevalence of obesity 
among AAs in the Unites States was 37.3% in adult men and 
49.6% in adult women, whereas the US national prevalence 
was 32.2% and 35.5% in adult men and women, respectively 
(1). Obesity increases the likelihood of developing a variety of 
chronic diseases including diabetes, hypertension, high cho-
lesterol, stroke, heart disease, cancers, and arthritis (2), lead-
ing to excess mortality and morbidity (3) and exerting a severe 
economic burden on the healthcare system (4). Environmental 
factors such as excessive energy intake and sedentary lifestyle 
are known to contribute to obesity. However, genetic factors 
have been found to strongly modulate an individual’s suscep-
tibility to obesity. Twin and family studies have estimated the 
heritability of BMI to range from 40 to 70% (5,6). However, 
genome-wide association studies (GWAS) based upon single-
nucleotide polymorphisms (SNPs) have only accounted for a 
modest proportion of the total genetic variation—a common 
finding known as missing heritability (7,8). Structural variants 
such as copy number variations (CNVs) have been suggested 
as a potential source of this missing heritability (7,8).
CNVs have been reported to be associated with human dis-
ease, disorders (9–12), and quantitative gene expression levels 
(13,14) that, in some cases, are likely to have functional effects 
(14,15). A recent study demonstrated that the white patients 
with onset of obesity before 10 years of age had significantly 
more large, rare deletions than controls (16). This finding was 
replicated in obese whites regardless of the age of onset (17). 
However, obese AAs were found to possess less burden of rare 
CNVs, measured by the total span of CNVs per individual 
and average length of CNVs, compared to AA controls (18). A 
genome-wide association study (GWAS) of obesity in children 
found eight rare CNVs that were exclusive to obese white and 
African-American children (19). A study on BMI in Chinese 
identified a CNV region which overlaps a gene-regulating 
energy homeostasis (20). This finding was replicated in whites 
(21). These studies suggest that CNVs may play an important 
role in the genetic architecture of obesity. A large scale survey 
of CNVs is needed to further understand the genetics of obes-
ity in AAs.
We conducted a CNV genome-wide association study 
on BMI and other obesity-related traits in two established 
African-American cohorts: the Genetic Epidemiology 
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Network of Arteriopathy (GENOA) and Hypertension Genetic 
Epidemiology Network (HyperGEN) from the National Heart, 
Lung and Blood Institute (NHLBI) Family Blood Pressure 
Program. Participants in both studies were genotyped on the 
Affymetrix 6.0 array—a platform which includes probes spe-
cifically designed for CNV analysis. We found three CNVs 
that were significantly associated with BMI and obesity-related 
traits after correcting for multiple testing. We also examined 
three previously reported CNVs linked to obesity (21–23), but 
found no evidence of association.
Methods and Procedures
sample
The GENOA study is a community-based study of hypertensive sib-
ships that aims to identify genes influencing blood pressure (24). AA 
subjects were enrolled in the field center in Jackson, MS. Sibships were 
recruited who met the eligibility requirement: at least two adults were 
clinically diagnosed with essential hypertension before age 60. Other 
siblings were invited to participate regardless of affection status. Data 
was collected in two phases: between 1995 and 2000, 1,854 subjects 
were examined; then between 2000 and 2004, 1,482 of these par-
ticipants were re-examined. The GENOA study was approved by the 
institutional review boards of the participating institutions, and each 
participant provided written informed consent.
The HyperGEN study is a family based cross-sectional study designed 
to identify genetic contributors to hypertension (25). AA men and women 
were enrolled from centers in Birmingham, AL and Forsyth County, NC. 
In the first recruitment phase, sibships were recruited who met eligibil-
ity requirements: probands with onset of hypertension by age 60 and 
one or more hypertensive siblings who were willing to participate in the 
study (1995–2000). In the second phase, the offspring of the hypertensive 
siblings were recruited (2000–2003). At present, 1,224 AA subjects have 
been enrolled in HyperGEN and have provided the necessary phenotypic 
and genetic data. The HyperGEN study was approved by the institutional 
review board of the participating institutions, and each participant pro-
vided written informed consent.
cnV analysis
Study participants in GENOA (N = 1,355) and HyperGEN (N = 1,224) 
were genotyped using the Affymetrix Genome-wide Human SNP Array 
6.0 platform. Genetic samples were excluded if they had an overall SNP 
call rate <95% or sex mismatch between genotypic and phenotypic 
measurement based upon quality control implementations. HyperGEN 
samples who had a disproportionately large number of copy number 
polymorphisms (>25%) or were genotyped in small batches (16 or less 
subjects per batch) were also excluded. Following these quality control 
procedures, 1,263 AAs from GENOA and 1,026 AAs from HyperGEN 
remained for the current study (92 and 198 were excluded from GENOA 
and HyperGEN, respectively). The Human Genome 18 reference build 
was used for probe localization.
The GENOA study used the Affymetrix Genotyping Console 3.0.1 to 
generate a reference genome by using all 1,263 raw intensity files (CEL 
files) from the Human SNP Array 6.0 platform (Affymetrix Genotyp-
ing Console 3.0.1 User Manual). The boundaries of the common CNV 
segments were determined using the predefined CNV regions (26). 
Genotype calls for these CNVs were determined using the Canary algo-
rithm (26). Any CNV call whose confidence score was <0.8 was excluded 
from the analysis (lower scores indicate more uncertainty), resulting in 
a 90% call rate. In total, we identified 1,130 CNV regions. Among these, 
24 regions were monomorphic (normal type for all subjects) and were 
excluded from the analyses.
The HyperGEN study also used the Human SNP Array 6.0 platform to 
generate raw intensity files. CNVs were called using the Canary applica-
tion within Birdsuite software, Version 1.5.5 (27). Samples were analyzed 
by batch to eliminate batch effects (28). CNV genotype calls with confi-
dence values >0.1 were removed from the analysis (higher scores indicate 
more uncertainty), resulting in a 92% call rate. In total, we identified 
1,285 CNV regions. Among these, 84 regions were monomorphic and 
were excluded from the analyses. The chromosomal boundaries and the 
copy number state in each study were exported and used in the associa-
tion analyses of BMI and related traits.
The Genotyping Console and the Birdsuite software have different 
implementations of the same Canary algorithm. Therefore, the confi-
dence scores from the two software packages have different ranges for 
high-quality CNV call. The confidence scores were used to exclude CNV 
calls with poor confidence. We chose the threshold to have ~10% overall 
missingness in both analysis datasets.
statistical analysis
We used a linear mixed effect model to test for CNV–BMI associations 
in each identified CNV region in each study population. This model 
included CNV, age, age-squared, and sex as fixed effect covariates and 
family as a random effect to adjust for familial correlations within the 
families. CNV was treated as an additive trait, using the integer CNVs 
obtained from Canary. Principal component analysis was used to adjust 
for population stratification (29). The first 10 PCs based on 762,766 
autosomal SNPs (MAF >0.01 and call rate >95%) from GENOA sam-
ples were calculated and incorporated into the mixed model as fixed 
effect covariates. Similarly, the first 10 PCs based on 823,728 autosomal 
SNPs from HyperGEN samples were included as covariates in the 
HyperGEN analysis. In extracting PCs, SNPs were removed from the 















Age (years), mean (SD) 58.0 (10.07) 59.3 (9.62) 57.4 (10.22) 44.3 (13.43) 43.1 (13.63) 45.0 (13.29)
Weight (kg), mean (SD) 88.3 (18.21) 90.3 (17.06) 87.4 (18.66) 90.9 (23.55) 92.3 (21.21) 90.4 (24.61)
Height (cm), mean (SD) 168.8 (8.94) 177.9 (6.47) 164.5 (6.39) 167.6 (8.90) 176.4 (6.81) 163.3 (6.26)
BMI, kg/m2, mean (SD) 31.1 (6.49) 28.5 (4.95) 32.3 (6.76) 32.4 (8.12) 29.6 (6.26) 33.8 (8.56)
Waist circumference 
(cm), mean (SD)
103.4 (16.25) 100.3 (12.10) 104.8 (17.67) 102.6 (18.71) 99.7 (16.57) 104.0 (19.51)
Hip circumference 
(cm), mean (SD)
113.2 (14.11) 105.6 (10.38) 116.7 (14.25) 114.4 (16.35) 107.9 (12.76) 117.7 (16.95)
Obese (BMI ≥30 kg/m2)    640 (50.7%)    128 (32.2%)    512 (59.2%)    570 (55.7%)    136 (40.5%)    434 (63.1%)
GENOA, Genetic Epidemiology Network of Arteriopathy; HyperGEN, Hypertension Genetic Epidemiology Network.
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calculation if they exhibited Mendelian inheritance errors, missingness 
>1%, MAF <1%, or failure of Hardy–Weinberg equilibrium in founders 
(HWE P value <0.001).
Associated CNVs were examined with other obesity-related traits: 
weight, hip circumference, and waist circumference. Identical linear 
mixed models were fit to perform the analyses on these continuous traits. 
We also stratified the sample into obese (BMI ≥30 kg/m2) and nonobese 
(BMI <30 kg/m2). The relationship between CNV and obesity status was 
examined using generalized estimating equations.
An inverse variance based meta-analysis was carried out using METAL 
software (30) to combine the results from GENOA and HyperGEN. This 
approach calculated a weighted sum effect size, where the effect size for 
each study was weighted by the estimated SEs. False discovery rate was 
calculated to adjust for multiple testing and a false discovery rate q value 
of 0.1 was set as the threshold for significance.
All statistical analyses were performed with R statistical environ-
ment version 2.9.0 from R Project (http://www.r-project.org/) and 
METAL (30).
results
Basic descriptive statistics of the sample from each study popu-
lation are summarized in Table 1. The GENOA and HyperGEN 
studies have similar sample sizes and phenotypic measure-
ments on the traits we examined.
CNVs identified in this study were classified into three cate-
gories: deletion (copy number is <2), duplication (copy number 
is >2) and mixture type (observed copy numbers are less and 
more than 2). Among the 1,106 CNVs called in GENOA, 186 
CNVs were mixed type, 750 CNVs were deletion type and 170 
were duplication type. Similarly, among the 1,201 CNVs called 
in HyperGen, 221 CNVs were mixed type, 779 CNVs were 
deletion type and 201 were duplication type. There were 782 
CNVs whose call types are consistent between these two stud-
ies, which suggest high quality CNV calls. Among these CNVs, 
566 were deletion type, 95 duplication type and 121 mixed type. 
In this study, we focused on previously reported CNV regions 
with relatively common frequency in the HapMap sample. We 
did not observe any large CNVs (length >500 kb) with fre-
quency lower than 1% in both GENOA and HyperGEN AA 
populations.
There were a total of 1,037 CNVs that were shared between 
GENOA and HyperGEN. Among the 1,037 CNVs that were 
included in the meta-analysis, 55 CNV regions had P value 
<0.05 in the meta-analysis. After adjusting for multiple test-
ing, three CNVs had q value <0.1: CNP11162, CNP10809, and 
CNP11421 (Table 2). CNP11162 is located on chromosome 6, 
162,416,281 to 162,423,724 bp with 1.7% of deletion; CNP10809 
is located on chromosome 4, 145,220,925 to 145,232,498 bp 
with 4.2% of deletion and 1.7% of duplication; and CNP11421 
is located on chromosome 8, 14,553,275 to 14,559,579 bp with 
1.2% of deletion and 0.04% of duplication. The percentage of 
deletion (0 and 1 copies) and duplication (3 and 4 copies) were 
the percentage of individuals who carried loss or gain among 
all the individuals from both GENOA and HyperGEN. All 
the three CNVs included deletions. Although CNP10809 was 
mixture type, a greater number of deletions than duplications 
were observed in this region (82 individuals had loss and 34 
individuals had gain). CNP11421 in HyperGEN was mixture 
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the three CNV regions show negative association with BMI, 
suggesting deletions in these regions may increase the risk of 
obesity. Figure 1 shows how BMI changes over different copies 
of CNVs in each study population.
Association analyses of these three CNVs with obesity, 
weight, hip circumference, and waist circumference were also 
conducted. Results are included in Table 3. As expected, these 
CNVs were found to be associated with most of the other obes-
ity-related traits. The number of each type of CNVs in obese 
and nonobese groups is shown in Table 4.
We also examined the three previous reported CNV regions 
associated with obesity: CNP59 located on chromosome 
1, 72,528,701 to 72,535,958 bp; CNP2150 located on chromo-
some 16, 19,853,151 to 19,874,863 bp, and CNP1732 located 
on chromosome 11, 55,130,608 to 55,209,585 (21–23). In our 
study, we found no evidence of association with these three 
CNVs: the P value for CNP59 was 0.367 in GENOA and 0.255 
in HyperGEN; the P value for CNP2150 was 0.420 in GENOA 
and 0.594 in HyperGEN; and the P value for CNP1732 was 
0.406 in GENOA and 0.005 in HyperGEN. Previous reports 
suggest low copy number in CNP1732 is correlated with obes-
ity in children (21). However, although we found CNP1732 to 
be significantly associated with BMI in HyperGEN, the associ-
ation was in the opposite direction: lower copy number is asso-
ciated with lower BMI. A meta-analysis examining these CNVs 
did not show evidence of an association with BMI (P value = 
0.150, 0.336, and 0.346 for CNV59, CNV2150, and CNV1732, 
respectively). Furthermore, we looked at the number of each 
CNV type in the obese group and the nonobese group. In 
GENOA, the number of deletions for CNP59, CNP2150 and 
CNP1732 were 31, 140, and 150 in the obese group compared 
to 38, 137, and 131 in the nonobese group. In HyperGEN, there 
were 97, 92, and 113 deletions in the obese group compared to 
82, 71, and 107 in the nonobese group, respectively. There was 
no evidence of an enrichment of CNV in either group.
dIscussIon
In this study, we performed genome-wide association analy-
ses between CNVs and BMI in two AA populations. A meta-
analysis suggested CNP11162, CNP10809, and CNP11421 
were significantly associated with BMI. We performed addi-
tional association analyses of those CNVs with other obes-
ity-related traits including weight, waist circumference, hip 
circumference, and dichotomized obesity, and found con-
sistently significant associations. These variants overlap with 
genes PARK2 (Parkinson protein 2, E3 ubiquitin protein 
ligase), GYPA (Glycophorin A), and SGCZ (Sarcoglycan, 
Zeta), respectively.
PARK2 encodes for parkin, a ubiquitin ligase. Recessive 
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Figure 1 The relationship of BMI and the three significant copy number variations (CNVs) (CNV11162, CNV10809, and CNV11421). (a) Box plots of 
BMI with different copies of CNVs in Genetic Epidemiology Network of Arteriopathy (GENOA); (b) box plots of BMI with different copies of CNVs in 
Hypertension Genetic Epidemiology Network (HyperGEN).
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Parkinson’s disease (31), which was characterized by dopamine 
degeneration in substantial nigral pathway. Animal stud-
ies confirmed that knockout of this gene in mice disrupted 
dopaminergic transmission in striatal area (32,33). Dopamine 
is known to play an important role in modulating reward sen-
sitivity, conditioning, and high-level cognitive control, which 
are all involved in the regulation of food intake (34) and there-
fore have a potential role in obesity. In one study, palatable food 
was shown to release dopamine in the dorsal striatum that is 
highly correlated with the level of pleasure subjects reported 
from eating the food (35). There is evidence from human 
imaging studies suggesting that obese individuals might have 
impairments in the dopaminergic pathway (36,37). Thus, it is 
possible that a deletion in part of PARK2 gene leads to defi-
cit in dopamine transmission that is involved in homeostatic 
regulation of food intake, and results in excessive food intake 
and obesity. Most recently, PARK2 knockout mice were found 
to resist body weight gain when they were exposed to a high 
fat diet during the age of 12–18 weeks, which suggests that this 
gene is involved in the regulation of fat intake (38). More inter-
estingly, a recent study found an intronic SNP in the PARK2 
gene associated with levels of several serum amino acids that 





N Type β SE P value N Type β SE P value P value
Weight (kg)
 CNP11162 1,263 Deletion –8.71 4.02 0.0305 1,021 Deletion –18.49 6.56 0.0048 0.0009
 CNP10809 1,008 Mixturea –5.08 1.82 0.0055 938 Mixturea –3.75 3.88 0.3197 0.0034
 CNP11421 1,258 Deletion –11.42 5.48 0.0375 1,023 Mixturea –21.02 6.04 0.0005 0.0001
Hip circumference (cm)
 CNP11162 1,263 Deletion –4.05 1.39 0.0036 1,021 Deletion –11.23 4.47 0.0120 0.0004
 CNP10809 1,008 Mixturea –2.31 0.63 0.0003 938 Mixturea –3.14 2.64 0.2234 0.0001
 CNP11421 1,258 Deletion –4.31 1.89 0.0229 1,023 Mixturea –13.62 4.07 0.0007 0.0005
Waist circumference (cm)
 CNP11162 1,263 Deletion –8.00 3.60 0.0265 1,021 Deletion –11.98 5.20 0.0202 0.0017
 CNP10809 1,008 Mixturea –4.60 1.64 0.0052 938 Mixturea –5.71 3.05 0.0568 0.0008
 CNP11421 1,258 Deletion –8.85 4.92 0.0723 1,023 Mixturea –11.61 4.70 0.0125 0.0024
Obesity (BMI ≥30 kg/m2)
 CNP11162 1,263 Deletion –0.66 0.45 0.1409 1,021 Deletion –0.91 0.77 0.2291 0.06203
 CNP10809 1,008 Mixturea –0.80 0.23 0.0004 938 Mixturea –0.26 0.45 1.000 0.0006
 CNP11421 1,258 Deletion –0.83 0.62 0.1804 1,023 Mixturea –1.23 0.80 0.0898 0.0454
CNV, copy number variation; GENOA, Genetic Epidemiology Network of Arteriopathy; HyperGEN, Hypertension Genetic Epidemiology Network.
aObserved copy numbers can be less or more than 2 (i.e., some individuals had either deletion or amplification creating mixture of individuals with deletion, 
amplification, or normal).





N Obese Nonobese N Obese Nonobese N Obese Nonobese
CNP11162 1 1,263 15 7 1,021 11 6 2,284 26 13
2 625 616 557 447 1182 1063
CNP10809 0 1,008 2 0 938 0 0 1,946 2 0
1 35 15 17 13 52 28
2 450 478 501 401 951 879
3 10 14 2 4 12 18
4 1 3 0 0 1 3
CNP11421 1 1,258 8 3 1,023 14 3 2,281 22 6
2 630 617 554 451 1,084 1,068
3 0 0 1 0 1 0
CNV, copy number variation; GENOA, Genetic Epidemiology Network of Arteriopathy; HyperGEN, Hypertension Genetic Epidemiology Network.
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are directly involved in metabolic pathway (39). The putative 
functional role of PARK2 on serum metabolites may assist fur-
ther understanding of the relationship between the deletion in 
PARK2 gene and obesity-related traits.
GYPA is a gene that bears the antigenic determinants for the 
MN and Ss blood groups (40), and SGCZ encodes a protein 
that is part of sarcoglycan complex which bridges the inner 
cyroskeleton and the extracellular matrix (41). Neither of these 
two genes has been reported to be associated with any obesity-
related traits.
In a recent large scale GWAS, two CNV regions on chro-
mosome 1 and 16 were reported to be associated with BMI in 
whites (22,23). Another recent family based GWAS reported 
one CNV region on chromosome 11 that was associated with 
early onset of extreme obesity (21). We identified CNVs over-
lapping with these reported regions (CNP59 overlaps with the 
chromosome 1 region, CNP2150 overlaps with the chromo-
some 16 region and CNP1732 overlaps with the chromosome 
11 region) and specifically examined whether these CNVs 
were associated with BMI in our study cohorts. However, we 
were unable to replicate these associations with BMI or other 
obesity-related traits. The frequencies of the three reported 
CNVs on chromosome 1, 16, and 11 (all of them are deletion 
polymorphisms) were 62, 13, and 28% in the reported studies 
of whites (21–23) whereas the frequencies of the overlapping 
CNVs (CNP59, CNP2150, and CNP1732) were 12, 21, and 
22% in our study cohorts. Also, the large sample sizes (32,387 
and 249,796 participants) or the family design of the reported 
studies increased the power to detect small effect sizes. Our 
combined study of 2,289 AAs may have limited power to detect 
effects of that size. For example, if we assume the frequency of 
the non-normal variants is 0.3 and effect size is 0.17, the power 
of our study is only 0.14 at an α level of 0.05.
We identified three CNVs that were associated with BMI and 
obesity in AA populations. While our results should be inter-
preted within the context of obesity in hypertensive families, 
we have highlighted a potential causal pathway in one of these 
genes (PARK2) that may lead to dysfunction in brain rewarding 
and cognitive control regulating food intake, and thus result in 
excessive or compulsive food intake and obesity. As CNVs in our 
reported genes have not been previously found to be associated 
with BMI in studies based on white populations, our findings 
reinforce the need to stratify or account for population differ-
ences in genetic studies, particularly when considering traits like 
obesity that exhibit differing patterns among populations.
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